SEATTLE, June 22, 2018 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company focused on developing non-invasive Photobiomodulation (PBM) therapies for ocular disorders and disease, announced CE Mark Certification for the European Union (EU) for the treatment of dry age-related macular degeneration (AMD) utilizing its LT-300 Light Delivery System. The “CE” mark is the… Continue reading

Posted on June 25th, 2018 in Press Releases | Comments Off on LumiThera LT-300 Device For Treating Dry Advanced Macular Degeneration Granted CE Mark

SEATTLE, May 1, 2018 /PRNewswire/ — LumiThera Inc., a clinical stage medical device company focused on developing non-invasive Photobiomodulation (PBM) therapies for ocular disorders and disease, presented topline final results from the LIGHTSITE I clinical trial for the treatment of dry age-related macular degeneration (AMD) utilizing its LT-300 Light Delivery System. The LIGHTSITE I data… Continue reading

Posted on May 1st, 2018 in Press Releases | Comments Off on LumiThera Presents LIGHTSITE I Dry AMD Top Line Final Data

SEATTLE, March 13, 2018 /PRNewswire/ — LumiThera Inc., a clinical stage medical device company focused on developing non-invasive photobiomodulation (PBM) therapies for ocular disorders and disease, today announces that Clark E. Tedford, Ph.D., Chief Executive Officer, is scheduled to present on Saturday, March 17, 2018 at 9:30 a.m. China Standard Time, at the 2018 Inaugural… Continue reading

Posted on March 16th, 2018 in Press Releases | Comments Off on LumiThera Inc. to Present at the 2018 Inaugural China Healthcare Investment & Partnering Symposium (CHIPS)

SEATTLE, Feb. 5, 2018 /PRNewswire/ — LumiThera, a clinical stage medical device company focused on developing photobiomodulation (PBM) therapies for ocular disorders and disease, today announced that it will participate in the 7th Annual Glaucoma 360 New Horizons Forum being held on Friday, February 9, 2018 at The Palace Hotel, in San Francisco. This meeting… Continue reading

Posted on February 5th, 2018 in Press Releases | Comments Off on LumiThera, Inc. to Participate in the 2018 Glaucoma 360 in San Francisco

SEATTLE, Jan. 4, 2018 /PRNewswire/ — LumiThera a clinical stage medical device company focused on developing non-invasive photobiomodulation (PBM) therapies for ocular disorders and disease, today announced that it will present at the Digital Medicine and MedTech ShowcaseTM 2018, to be held January 8-10 during the most important week in healthcare at the Parc 55… Continue reading

Posted on January 5th, 2018 in Press Releases | Comments Off on LumiThera to Present at the Digital Medicine and MedTech ShowcaseTM Annual Conference on January 10, 2018

SEATTLE, November 7, 2017 /PRNewswire/ — LumiThera Inc., a clinical stage medical device company focused on developing non-invasive photobiomodulation (PBM) therapies for ocular disorders and disease, today announced topline interim results from the LIGHTSITE I trial for treatment of dry age-related macular degeneration (AMD) trial utilizing its LT-300 device. The 30-subject pilot study funded from… Continue reading

Posted on November 7th, 2017 in Press Releases | Comments Off on LumiThera Unveils LIGHTSITE I Dry AMD Clinical Interim Data

SEATTLE, October 31, 2017 /PRNewswire/ — LumiThera Inc., a clinical stage private medical device company creating a non-invasive photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has completed the Series B round of financing. The company raised $5.5M to support further development of its LT-300 device for the treatment for dry Age-related… Continue reading

Posted on October 31st, 2017 in Press Releases | Comments Off on LumiThera Closes Series B Round of Financing

SEATTLE, April 18, 2017 /PRNewswire/ — LumiThera® Inc., a clinical stage medical device company focused on delivering non-invasive photobiomodulation (PBM) therapies for ocular disorders and disease, today announced it has been awarded the prestigious “MOST INNOVATIVE AND PROMISING MEDTECH & E-HEALTH COMPANY” during Biovision 2017 in Lyon, France. Biovision is a high-level investor event connecting… Continue reading

Posted on April 18th, 2017 in Press Releases | Comments Off on LumiThera Named Most Innovative And Promising Medtech & E-Health Company At Biovision 2017

SEATTLE, May 5, 2016 /PRNewswire/ — LumiThera® Inc., a late stage developmental medical device company creating a non-invasive photobiomodulation (PBM) treatment for ocular disorders and disease today announced that Graham Merry, MBBS presented clinical data results from the TORPA II study in Dry Age-Related Macular Degeneration (AMD) subjects at the Association for Research in Vision… Continue reading

Posted on May 6th, 2016 in Press Releases | Comments Off on LumiThera Presents Results of TORPA II Clinical Study at the Association for Research in Vision and Ophthalmology (ARVO) Conference

SEATTLE, April 27, 2016 /PRNewswire/ — LumiThera ® Inc., a late-stage developmental medical device company creating a non-invasive photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it has been awarded the prestigious “MOST PROMISING AND INNOVATIVE CATALYZER AWARD” during Biovision 2016, Lyon, France. Biovision is a high-level investor event connecting industrial partners, financial… Continue reading

Posted on April 28th, 2016 in Press Releases | Comments Off on LumiThera Named Most Promising and Innovative Catalyzer Startup at BIOVISION 2016